Fabrizio Martora

Dr. Fabrizio Martora

University of Naples Federico II, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2022 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
ARAngelo Ruggiero
Angelo Ruggiero
VPVincenzo Picone
Vincenzo Picone
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
GFGabriella Fabbrocini
Gabriella Fabbrocini
MMMatteo Megna
Matteo Megna
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.

13 October 2022 in Dermatologic Therapy
Verified
Journal Article
Open access
Maddalena NapolitanoMaddalena Napolitano
Maddalena Napolitano
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
LGLucia Genco
Lucia Genco
MNMatteo Noto
Matteo Noto
CPCataldo Patruno
Cataldo Patruno
Atopic dermatitis (AD) is a chronic inflammatory, itching skin with a significant psychosocial impact on patients and relatives. In adults and adolescents besides flexural eczema, head and neck eczema, and hand eczema, which are the most frequent clinical phenotypes (84.9% and 84.2%, respectively), there are also other possible presentation such as, portrait‐like dermatitis (20.1%), diffuse eczema (6.5%), eczema nummulare‐like (5.8%), prurigo nodularis‐like (2.1%) and erythrodermia (0.7%). Diagnosis can be easy due to the typically distributed eczematous lesions, albeit with age‐related differences, However, it is also extremely heterogeneous in severity, course, and sometimes particular clinical features. Currently, there are no better diagnostic criteria than an experienced dermatologist for the diagnosis of AD. Misdiagnosis and delayed treatment will have an impact not only on the child's physical health, but also and especially on the child's psychological health. The aim of our review was to group the main differential diagnoses in pediatric age where the diagnosis can often hide many pitfalls.

1 January 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
MMMatteo Megna
Matteo Megna
TBTeresa Battista
Teresa Battista
LPLuca Potestio
Luca Potestio
MAMaria Carmela Annunziata
Maria Carmela Annunziata
GFGabriella Fabbrocini
Gabriella Fabbrocini
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current evidence from literature on the use of biologics in HS in a real-life setting, particularly adalimumab, secukinumab and ustekinumab. Data on the effectiveness and safety of biologic drugs in HS management have been analyzed. Even if the results are promising, more studies are needed. In our opinion, the armamentarium of drugs for HS management is increasing, and treatment will be based on a tailored-tail approach, minimizing the risk of adverse events. In this context, we want to point out the reported effectiveness and safety data concerning adalimumab, ustekinumab and secukinumab as well as ixekizumab.

1 April 2024 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
LPLuca Potestio
Luca Potestio
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
GLGiuseppe Lauletta
Giuseppe Lauletta
YVYlenia Vallone
Ylenia Vallone
TBTeresa Battista
Teresa Battista
MMMatteo Megna
Matteo Megna
Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing the pivotal role of this axis has facilitated the development of selective and effective biological drugs, such as anti-IL17 and anti-IL23 monoclonal antibodies. These drugs aim to achieve the complete or near-complete disappearance of psoriatic lesions, as indicated by PASI100 and PASI90 responses, respectively. In this context, the aim of our review was to delve into the functioning of the IL-23/Th17 axis, its dysregulation in psoriasis pathogenesis, and the therapeutic potential of its inhibition. Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have been approved. All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics’ profile, in order to administer the right drug for the right patients at the right moment.

16 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
Maddalena NapolitanoMaddalena Napolitano
Maddalena Napolitano
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
VPVincenzo Picone
Vincenzo Picone
PMPaola Morelli
Paola Morelli
Cataldo PatrunoCataldo Patruno
Cataldo Patruno
Aryl Hydrocarbon Receptor (AhR) is an evolutionary transcription factor which acts as a crucial sensor of different exogenous and endogenous molecules Recent data indicate that AhR is implicated in several physiological processes such as cell physiology, host defense, proliferation and differentiation of immune cells, and detoxification. Moreover, AhR involvement has been reported in the development and maintenance of several pathological conditions. In recent years, an increasing number of studies have accumulated highlighting the regulatory role of AhR in the physiology of the skin. However, there is evidence of both beneficial and harmful effects of AHR signaling. At present, most of the evidence concerns inflammatory skin diseases, in particular atopic dermatitis, psoriasis, acne, and hidradenitis suppurativa. This review exam-ines the role of AhR in skin homeostasis and the therapeutic implication of its pharmacological modulation in these cutaneous inflammatory diseases.

16 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ARAngelo Ruggiero
Angelo Ruggiero
Fabrizio MartoraFabrizio Martora
Fabrizio Martora
VPVincenzo Picone
Vincenzo Picone
LMLaura Marano
Laura Marano
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini
Claudio MarascaClaudio Marasca
Claudio Marasca
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease usually occurring after puberty with painful, deep-seated, inflammatory lesions in the apocrine gland-bearing areas of the body. Although HS pathogenesis is still unproven, recent major research advantages have increased our knowledge of the mechanisms behind HS lesions. Particularly, follicular occlusion followed by follicular rupture has been shown to be crucial to HS development, leading to immune response activation, and resulting in typical clinical HS lesions. Moreover, an increased and imbalanced cytokine production, such as interleukin (IL) 17 and tumor necrosis factor (TNF) α, may play a role in HS. In recent years, paradoxical adverse events have been described during treatment. Since the recent increased use of biologic treatments in HS, an increased number of paradoxical HS occurrences have been reported. In this review, we analyzed all current data on paradoxical HS triggered by biological drugs.